Lanreotide Therapy in Carcinoid Syndrome: Prospective Analysis of Patient-reported Symptoms in Patients Responsive to Prior Octreotide Therapy and Patients Naïve to Somatostatin Analogue Therapy in the Elect Phase 3 Study.

@article{Fisher2018LanreotideTI,
  title={Lanreotide Therapy in Carcinoid Syndrome: Prospective Analysis of Patient-reported Symptoms in Patients Responsive to Prior Octreotide Therapy and Patients Na{\"i}ve to Somatostatin Analogue Therapy in the Elect Phase 3 Study.},
  author={G. A. Fisher and Edward M. Wolin and Nilani Liyanage and Susan Pitman Lowenthal and Beloo Mirakhur and Rodney F. Pommier and Montaser Shaheen and Aaron I Vinik},
  journal={Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists},
  year={2018},
  volume={24 3},
  pages={243-255}
}
OBJECTIVE This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naïve to prior somatostatin analogue treatment (de novo group). METHODS Adults with… CONTINUE READING